Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Dec 3;2015(12):CD009745.
doi: 10.1002/14651858.CD009745.pub2.

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Daniel Simancas-Racines  1 , Dimelza Osorio, Arturo J Martí-Carvajal, Ingrid Arevalo-Rodriguez
Affiliations
Meta-Analysis

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Daniel Simancas-Racines et al. Cochrane Database Syst Rev. .

Abstract

Background: A blood transfusion is an acute intervention, implemented to solve life and health-threatening conditions on a short-term basis. However, blood transfusions have adverse events, some of them potentially related to immune modulation or to a direct transmission of infectious agents (e.g. cytomegalovirus). Leukoreduction is a process in which the white blood cells are intentionally reduced in packed red blood cells (PRBCs) in order to reduce the risk of adverse reactions. The potential benefits of leukoreduced PRBCs in all types of transfused patients for decreasing infectious and non-infectious complications remain unclear.

Objectives: To determine the clinical effectiveness of leukoreduction of packed red blood cells for preventing adverse reactions following allogeneic blood transfusion.

Search methods: We ran the most recent search on 10th November 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library), MEDLINE (OvidSP), Embase(OvidSP), CINAHL Plus (EBSCO), LILACS (BIREME), and clinical trials registers. In addition, we checked the reference lists of all relevant trials and reviews identified in the literature searches.

Selection criteria: Randomised clinical trials including patients of all ages requiring PRBC allogeneic transfusion. Any study was eligible for inclusion, regardless of the length of participant follow-up or country where the study was performed. The primary outcome was transfusion-related acute lung injury (TRALI). Secondary outcomes were death from any cause, infection from any cause, non-infectious complications and any other adverse event.

Data collection and analysis: At least two review authors independently performed study selection, 'Risk of bias' assessments and data extraction. We estimated pooled relative risk for dichotomous outcomes, and we measured statistical heterogeneity using I² statistic. The random-effects model was used to synthesise results. We conducted a trial sequential analysis to assess the risk of random errors in cumulative meta-analyses.

Main results: Thirteen studies, most including adult patients, met the eligibility criteria. We found no clear evidence of an effect of leukoreduced PRBC versus non-leukoreduced PRBC in patients that were randomised to receive transfusion for the following outcomes: TRALI: RR 0.96, 95% CI 0.67 to 1.36, P = 0.80 from one trial reporting data on 1864 trauma patients. The accrued information of 1864 participants constituted only 28.5% of the diversity-adjusted required information size (DARIS) of 6548 participants. The quality of evidence was low. Death from any cause: RR 0.81, 95% CI 0.58 to 1.12, I² statistic = 63%, P = 0.20 from nine trials reporting data on 6485 cardiovascular surgical patients, gastro-oncology surgical patients, trauma patients and HIV infected patients. The accrued information of 6485 participants constituted only 55.3% of the DARIS of 11,735 participants. The quality of evidence was very low. Infection from any cause: RR 0.80, 95% CI 0.62 to 1.03, I² statistic = 84%, P = 0.08 from 10 trials reporting data on 6709 cardiovascular surgical patients, gastro-oncology surgical patients, trauma patients and HIV infected patients. The accrued information of 6709 participants constituted only 60.6% of the DARIS of 11,062 participants. The quality of evidence was very low. Adverse events: The only adverse event reported as an adverse event was fever (RR 0.81, 95% CI 0.64 to 1.02; I² statistic= 0%, P = 0.07). Fever was reported in two trials on 634 cardiovascular surgical and gastro-oncology surgical patients. The accrued information of 634 participants constituted only 84.4% of the DARIS of 751 participants. The quality of evidence was low. Incidence of other non-infectious complications: This outcome was not assessed in any included trial.

Authors' conclusions: There is no clear evidence for supporting or rejecting the routine use of leukoreduction in all patients requiring PRBC transfusion for preventing TRALI, death, infection, non-infectious complications and other adverse events. As the quality of evidence is very low to low, more evidence is needed before a definitive conclusion can be drawn.

PubMed Disclaimer

Conflict of interest statement

IA‐R: None known.

AM‐C: None known.

DO: None known.

DS‐R: None known.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.
4
4
TSA calculated to reliably detect a 25% relative change in the incidence of death from any cause, assuming a control group event rate of 9.34% with a power of 80% at an alpha of 5%
5
5
Funnel plot of comparison: 1 Leukoreduced PRBC versus non‐leukoreduced PRBC. Main Analysis (Randomised patients), outcome: 1.3 Infection. Number of events of the total of randomised patients reported.
6
6
TSA calculated to reliably detect a 25% relative change in the incidence of infection from any cause, assuming a control group event rate of 20.4% with a power of 80% at an alpha of 5%.
7
7
TSA calculated to reliably detect a 25% relative change in the incidence of fever, assuming a control group event rate of 38.7% with a power of 80% at an alpha of 5%.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009745

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Bilgin 2004 {published data only}
    1. Bilgin YM, Watering LM, Eijsman L, Versteegh MI, Brand R, Oers MH, et al. Double‐blind, randomized controlled trial on the effect of leukocyte‐depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004;109(22):2755‐60. [PUBMED: 15148271] - PubMed
Boshkov 2006 {published data only}
    1. Boshkov LK, Chien G, VanWinkle D, Furnary AP, Wu Y, Grunkemeirer GI, et al. Prestorage leukoreduction of transfused packed red cells is associated with significant ongoing 1‐12 month survival benefit cardiac surgery patients. Blood 2006;108:578.
Collier 2001 {published data only}
    1. Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, et al. Leukocyte‐reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001;285(12):1592‐601. [PUBMED: 11268267] - PubMed
    1. Lane TA, Gernsheimer T, Mohandas K, Assmann SF. Signs and symptoms associated with the transfusion of WBC‐reduced RBCs and non‐WBC‐reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study. Transfusion 2002;42(2):265‐74. [PUBMED: 11896345] - PubMed
Donati 2014 {published data only}
    1. Donati A, Damiani E, Luchetti M, Domizi R, Scorcella C, Carsetti A, et al. Microcirculatory effects of the transfusion of leukodepleted or non‐leukodepleted red blood cells in patients with sepsis: a pilot study. Critical Care 2014;18(1):R33. [PUBMED: 24528648] - PMC - PubMed
Jensen 1996 {published data only}
    1. Jensen LS, Kissmeyer‐Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte‐depleted versus buffy‐coat‐poor blood transfusion and complications after colorectal surgery. Lancet 1996;348(9031):841‐5. [PUBMED: 8826808] - PubMed
Lapierre 2007 {published data only}
    1. Lapierre V, Aupérin A, Robinet E, Ferrand C, Oubouzar N, Tramalloni D, et al. Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study. Transfusion 2007;47(9):1691‐9. [PUBMED: 17725736] - PubMed
Nathens 2006 {published data only}
    1. Nathens AB, Nester TA, Rubenfeld GD, Nirula R, Gernsheimer TB. The effects of leukoreduced blood transfusion on infection risk following injury: a randomized controlled trial. Shock 2006;26(4):342‐7. [PUBMED: 16980879] - PubMed
    1. Watkins TR, Rubenfeld GD, Martin TR, Nester TA, Caldwell E, Billgren J, et al. Effects of leukoreduced blood on acute lung injury after trauma: a randomized controlled trial. Critical Care Medicine 2008;36(5):1493‐9. [PUBMED: 18434890] - PubMed
Sanfilippo 1985 {published data only}
    1. Sanfilippo FP, Bollinger RR, MacQueen JM, Brooks BJ, Koepke JA. A randomized study comparing leukocyte‐depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients. Transfusion 1985;25(2):116‐9. [PUBMED: 3885483] - PubMed
Tartter 1998 {published data only}
    1. Tartter PI, Mohandas K, Azar P, Endres J, Kaplan J, Spivack M. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. American Journal of Surgery 1998;176(5):462‐6. [PUBMED: 9874434] - PubMed
Titlestad 2001 {published data only}
    1. Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Qvist N, Georgsen J. Leukocyte‐depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double‐blinded, randomized study. International Journal of Colorectal Disease 2001;16(3):147‐53. [PUBMED: 11459288] - PubMed
van de Watering 1998 {published data only}
    1. Watering LM, Hermans J, Houbiers JG, Broek PJ, Bouter H, Boer F, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998;97(6):562‐8. [PUBMED: 9494026] - PubMed
van Hilten 2004 {published data only}
    1. Lange MM, Hilten JA, Watering LM, Bijnen BA, Roumen RM, Putter H, et al. Leucocyte depletion of perioperative blood transfusion does not affect long‐term survival and recurrence in patients with gastrointestinal cancer. The British Journal of Surgery 2009;96(7):734‐40. [PUBMED: 19526613] - PubMed
    1. Hilten JA, Watering LM, Bockel JH, Velde CJ, Kievit J, Brand R, et al. Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. BMJ 2004;328(7451):1281. [PUBMED: 15142885] - PMC - PubMed
Wallis 2002 {published data only}
    1. Wallis JP, Chapman CE, Orr KE, Clark SC, Forty JR. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002;42(9):1127‐34. [PUBMED: 12430668] - PubMed

References to studies excluded from this review

Bowden 1995 {published data only}
    1. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, et al. A comparison of filtered leukocyte‐reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion‐associated CMV infection after marrow transplant. Blood 1995;86(9):3598‐603. [PUBMED: 7579469] - PubMed
Bracey 2002 {published data only}
    1. Bracey AW, Radovancevic R, Nussmeier NA. Leukocyte‐depleted blood in open‐heart surgery patients: effects on outcome. Transfusion 2002;42(Suppl):5S.
Connery 2005 {published data only}
    1. Connery CP, Toumpoulis IK, Anagnostopoulos CE, Hillel Z, Rahman FG, Katritsis D, et al. Does leukofiltration reduce pulmonary infections in CABG patients? A prospective, randomized study with early results and mid‐term survival. Acta Cardiologica 2005;60(3):285‐93. [PUBMED: 15999468] - PubMed
de Vries 2003 {published data only}
    1. Vries AJ, Gu YJ, Post WJ, Vos P, Stokroos I, Lip H, et al. Leucocyte depletion during cardiac surgery: a comparison of different filtration strategies. Perfusion 2003;18(1):31‐8. [PUBMED: 12705648] - PubMed
de Vries 2004 {published data only}
    1. Vries AJ, Gu YJ, Oeveren W. Leucocyte filtration of residual heart‐lung machine blood in children undergoing congenital heart surgery. Perfusion 2004;19(6):345‐9. [PUBMED: 15619967] - PubMed
Dzik 2002 {published data only}
    1. Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42(9):1114‐22. [PUBMED: 12430666] - PubMed
Efstathiou 2003 {published data only}
    1. Efstathiou A, Vlachveis M, Tsonis G, Asteri T, Psarakis A, Fessatidis IT. Does leukodepletion during elective cardiac surgery really influence the overall clinical outcome?. The Journal of Cardiovascular Surgery 2003;44(2):197‐204. [PUBMED: 12813383] - PubMed
Gilbert 1989 {published data only}
    1. Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion‐acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet (London, England) 1989;1(8649):1228‐31. [PUBMED: 2566781] - PubMed
Gu 1996 {published data only}
    1. Gu YJ, Vries AJ, Boonstra PW, Oeveren W. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery 1996;112(2):494‐500. [PUBMED: 8751518] - PubMed
Gu 2009 {published data only}
    1. Gu YJ, Vries AJ, Hagenaars JA, Oeveren W. Leucocyte filtration of salvaged blood during cardiac surgery: effect on red blood cell function in concentrated blood compared with diluted blood. European Journal of Cardio‐Thoracic Surgery 2009;36(5):877‐82. [PUBMED: 19608429] - PubMed
Hayashi 2000 {published data only}
    1. Hayashi Y, Sawa Y, Nishimura M, Ichikawa H, Kagisaki K, Ohtake S, et al. Clinical evaluation of leukocyte‐depleted blood cardioplegia for pediatric open heart operation. The Annals of Thoracic Surgery 2000;69(6):1914‐9. [PUBMED: 10892946] - PubMed
Houbiers 1994 {published data only}
    1. Houbiers JG, Brand A, Watering LM, Hermans J, Verwey PJ, Bijnen AB, et al. Randomised controlled trial comparing transfusion of leucocyte‐depleted or buffy‐coat‐depleted blood in surgery for colorectal cancer. Lancet 1994;344(8922):573‐8. [PUBMED: 7914960] - PubMed
    1. Watering LM, Brand A, Houbiers JG, Klein Kranenbarg WM, Hermans J, Velde C. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. The British Journal of Surgery 2001;88(2):267‐72. [PUBMED: 11167879] - PubMed
Jensen 1992 {published data only}
    1. Jensen LS, Andersen AJ, Christiansen PM, Hokland P, Juhl CO, Madsen G, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. The British Journal of Surgery 1992;79(6):513‐6. [PUBMED: 1611441] - PubMed
    1. Jensen LS, Hokland M, Nielsen HJ. A randomized controlled study of the effect of bedside leucocyte depletion on the immunosuppressive effect of whole blood transfusion in patients undergoing elective colorectal surgery. The British Journal of Surgery 1996;83(7):973‐7. [PUBMED: 8813790] - PubMed
Kao 1995 {published data only}
    1. Kao KJ, Mickel M, Braine HG, Davis K, Enright H, Gernsheimer T, et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. The Trap Study Group. Transfusion 1995;35(1):13‐9. [PUBMED: 7998062] - PubMed
Koskenkari 2005 {published data only}
    1. Koskenkari J, Rimpiläinen J, Biancari F, Surcel HM, Kaukoranta P, Kiviluoma K, et al. Leukocyte depleting filter attenuates myocardial injury during elective coronary artery bypass surgery. Scandinavian Cardiovascular Journal 2005;39(6):358‐68. [PUBMED: 16352489] - PubMed
Leal‐Noval 2005 {published data only}
    1. Leal‐Noval SR, Amaya R, Herruzo A, Hernández A, Ordóñez A, Marín‐Niebla A, et al. Effects of a leukocyte depleting arterial line filter on perioperative morbidity in patients undergoing cardiac surgery: a controlled randomized trial. The Annals of Thoracic Surgery 2005;80(4):1394‐400. [PUBMED: 16181877] - PubMed
Llewelyn 2004 {published data only}
    1. Llewelyn CA, Taylor RS, Todd AA, Stevens W, Murphy MF, Williamson LM. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion 2004;44(4):489‐500. [PUBMED: 15043563] - PubMed
Nielsen 1999 {published data only}
    1. Nielsen HJ, Hammer JH, Krarup AL, Nielsen LM, Reimert CM, Pedersen AN, et al. Prestorage leukocyte filtration may reduce leukocyte‐derived bioactive substance accumulation in patients operated for burn trauma. Burns 1999;25(2):162‐70. [PUBMED: 10208393] - PubMed
Opelz 1997 {published data only}
    1. Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997;63(7):964‐7. [PUBMED: 9112348] - PubMed
Salamonsen 2005 {published data only}
    1. Salamonsen RF, Anderson J, Anderson M, Bailey M, Magrin G, Rosenfeldt F. Total leukocyte control for elective coronary bypass surgery does not improve short‐term outcome. The Annals of Thoracic Surgery 2005;79(6):2032‐8. [PUBMED: 15919304] - PubMed
Skånberg 2007 {published data only}
    1. Skånberg J, Lundholm K, Haglind E. Effects of blood transfusion with leucocyte depletion on length of hospital stay, respiratory assistance and survival after curative surgery for colorectal cancer. Acta Oncologica 2007;46(8):1123‐30. [PUBMED: 17851860] - PubMed
So‐Osman 2010 {published data only}
    1. So‐Osman C, Nelissen R, Slaa R, Coene L, Brand R, Brand A. A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte‐depleted red blood cells. Vox Sanguinis 2010;98(1):56‐64. [PUBMED: 19656349] - PubMed
Vamvakas 2007 {published data only}
    1. Vamvakas EC. White‐blood‐cell‐containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta‐analysis. Vox Sanguinis 2007;92(3):224‐32. [PUBMED: 17348871] - PubMed
van de Watering 2004 {published data only}
    1. Watering L. What has universal leucodepletion given us: evidence from clinical trials?. Vox Sanguinis 2004;87 Suppl 2:139‐42. [PUBMED: 15209899] - PubMed

References to studies awaiting assessment

NCT00810810 {published data only}
    1. Immunomodulation Following Transfusion. https://clinicaltrials.gov/ct2/show/NCT00810810.
Waghmare 2012 {published data only}
    1. Waghmare N, Desai N, Karnad D. Open Labeled, Randomized, Controlled Trial Comparing Leukodepleted (Filtered) Blood Transfusion and Non‐Leukodepleted (Unfiltered) Blood Transfusion in Cases of Severe Falciparum Malaria. Chest. Glenview (IL): Proceedings of the CHEST 2012 Annual Meeting, Atlanta (GA), October 2012; Vol. 142:Meeting Abstracts: 232A.
Zhao 2004 {published data only}
    1. Zhao S, Chen X, Hu J, Li R. Clinical assessment of preventing febrile nonhemolytic transfusion reaction by leukocyte‐depleted blood transfusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi [Journal of Experimental Hematology] 2002;10(6):568‐70. [PUBMED: 12513724 ] - PubMed

Additional references

AETSA 2007
    1. Aguado M, Villegas R, Márquez S, Corbacho B, Navarro J. Universal leukorreduction. A systematic review of the literature and an economic assessment. Executive summary [Leucorreducción universal de productos sanguíneos. Revisión Sistemática de la Literatura y Evaluación Económica.]. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía 2007:1‐95.
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401‐6. [PUBMED: 21208779] - PubMed
Blajchman 2002
    1. Blajchman MA. Immunomodulation and blood transfusion. American Journal of Therapeutics 2002;9(5):389‐95. [PUBMED: 12237730] - PubMed
Blajchman 2004
    1. Blajchman MA, Goldman M, Webert KE, Vamvakas EC, Hannon J, Delage G. Proceedings of a consensus conference: the screening of blood donors for variant CJD. Transfusion Medicine Reviews 2004;18(2):73‐92. [PUBMED: 15067588] - PubMed
Blajchman 2006
    1. Blajchman MA. The clinical benefits of the leukoreduction of blood products. The Journal of Trauma 2006;60(6 Suppl):S83‐90. [PUBMED: 16763486] - PubMed
Blajchman 2010
    1. Blajchman MA, Glynn SA, Josephson CD, Kleinman SH, State‐of‐the Science Symposium Transfusion Medicine Committee. Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State‐of‐the‐Science Symposium. Transfusion Medicine Reviews 2010;24(4):259‐85. [PUBMED: 20851330] - PubMed
Blumberg 1998
    1. Blumberg N. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta‐analysis of unconfounded studies. The British Journal of Surgery 1998;85(8):1163‐4. [PUBMED: 9718033] - PubMed
Blumberg 2007
    1. Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH. The intention‐to‐treat principle in clinical trials and meta‐analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007;47(4):573‐81. [PUBMED: 17381614] - PubMed
Blumberg 2010
    1. Blumberg N, Heal JM, Gettings KF, Phipps RP, Masel D, Refaai MA, et al. An association between decreased cardiopulmonary complications (transfusion‐related acute lung injury and transfusion‐associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010;50(12):2738‐44. [PUBMED: 20561296] - PMC - PubMed
Brozek 2011
    1. Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011;66(5):588‐95. [PUBMED: 21241318] - PubMed
Carson 2012
    1. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD002042.pub3; PUBMED: 22513904] - DOI - PMC - PubMed
CCOHTA 1998
    1. Gibis B, Baladi JF. Leukoreduction: the techniques used, their effectiveness and costs. Canadian Coordinating Office for Health Technology Assessmnet (CCOHTA). https://www.cadth.ca/sites/default/files/pdf/leukoreduct_tr_e.pdf (accessed 15 August 2015). [IBSN 1‐895561‐60‐4]
Chan 2013
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ Clinical Research 2013;346:e7586. [PUBMED: 23303884] - PMC - PubMed
Chandler 2013
    1. Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D. Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.3. 02 December 2013. http://editorial‐unit.cochrane.org/sites/editorial‐unit.cochrane.org/files/uploads/MECIR_... (accessed 20 September 2014).
Dellinger 2004
    1. Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Critical Care 2004;8(Suppl 2):S18‐23. [PUBMED: 15196317] - PMC - PubMed
Dwyre 2008
    1. Dwyre DM, Holland PV. Transfusion‐associated graft‐versus‐host disease. Vox Sanguinis 2008;95(2):85‐93. [PUBMED: 18544121] - PubMed
Fergusson 2004
    1. Fergusson D, Khanna MP, Tinmouth A, Hébert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta‐analyses of randomized controlled trials. Canadian Journal of Anaesthesia (Journal Canadien d'Anesthésie) 2004;51(5):417‐24. [PUBMED: 15128625] - PubMed
Flohé 2007
    1. Flohé S, Kobbe P, Nast‐Kolb D. Immunological reactions secondary to blood transfusion. Injury 2007;38(12):1405‐8. [PUBMED: 18048035] - PubMed
Friese 2008
    1. Friese RS, Sperry JL, Phelan HA, Gentilello LM. The use of leukoreduced red blood cell products is associated with fewer infectious complications in trauma patients. American Journal of Surgery 2008;196(1):56‐61. [PUBMED: 18513694] - PubMed
Gabriel 2012
    1. Gabriel SE, Normand SL. Getting the methods right‐‐the foundation of patient‐centered outcomes research. The New England Journal of Medicine 2012;367(9):787‐90. [PUBMED: 22830434] - PubMed
Galel 2009
    1. Galel SA, Nguyen DD, Fontaine MJ, Goodnough LT, Viele MK. Transfusion Medicine. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA editor(s). Wintrobe's Clinical Hematology. 12th Edition. Vol. 1, Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009:672‐721.
Goldman 2005
    1. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfusion Medicine Reviews 2005;19(1):2‐31. [PUBMED: 15830325] - PubMed
GRADEpro GDT [Computer program]
    1. Evidence Prime, Inc. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University. Evidence Prime, Inc, 2015.
Guyatt 2011a
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [PUBMED: 21195583] - PubMed
Guyatt 2011b
    1. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology 2011;64(12):1283‐93. [PUBMED: 21839614] - PubMed
Guyatt 2011c
    1. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395‐400. [PUBMED: 21194891] - PubMed
Guyatt 2011d
    1. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302. [PUBMED: 21803546] - PubMed
Guyatt 2011e
    1. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence‐‐indirectness. Journal of Clinical Epidemiology 2011;64(12):1303‐10. [PUBMED: 21802903] - PubMed
Guyatt 2011f
    1. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence‐‐publication bias. Journal of Clinical Epidemiology 2011;64(12):1277‐82. [PUBMED: 21802904] - PubMed
Guyatt 2011g
    1. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso‐Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence‐‐study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407‐15. [PUBMED: 21247734] - PubMed
Guyatt 2011h
    1. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso‐Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311‐6. [PUBMED: 21802902] - PubMed
Heddle 1999
    1. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Current Opinion in Hematology 1999;6(6):420‐6. [PUBMED: 10546797] - PubMed
Hendrickson 2009
    1. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesthesia and Analgesia 2009;108(3):759‐69. [PUBMED: 19224780] - PubMed
Hiesse 2001
    1. Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, et al. Multicenter trial of one HLA‐DR‐matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney International 2001;60(1):341‐9. [PUBMED: 11422770] - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [PUBMED: 12958120] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoffman 2008
    1. Hoffman R, Furie B, McGlave P, Silberstein LE, Shattil SJ, Benz EJ, et al. Hematology: Basic Principles and Practice. 5th Edition. London: Churchill Livingstone, 2008.
Jensen 1998
    1. Jensen LS. Benefits of leukocyte‐reduced blood transfusions in surgical patients. Current Opinion in Hematology 1998;5(6):376‐80. [PUBMED: 9814642] - PubMed
King 2004
    1. King KE, Shirey RS, Thoman SK, Bensen‐Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004;44(1):25‐9. [PUBMED: 14692963] - PubMed
Laupacis 2001
    1. Laupacis A, Brown J, Costello B, Delage G, Freedman J, Hume H, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001;41(4):560‐9. [PUBMED: 11316911] - PubMed
Lavoie 2011
    1. Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. Paediatric Anaesthesia 2011;21(1):14‐24. [PUBMED: 21155923] - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Lindholm 2011
    1. Lindholm PF, Annen K, Ramsey G. Approaches to minimize infection risk in blood banking and transfusion practice. Infectious Disorders Drug Targets 2011;11(1):45‐56. [PUBMED: 21303341] - PubMed
Looney 2006
    1. Looney MR, Su X, Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion‐related acute lung injury. The Journal of Clinical Investigation 2006;116(6):1615‐23. [PUBMED: 16710475] - PMC - PubMed
Martí‐Carvajal 2010
    1. Martí‐Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodriguez‐Malagon N. Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD007539] - DOI - PMC - PubMed
Mukagatare 2010
    1. Mukagatare I, Monfort M, Marchin J, Gerard C. The effect of leukocyte‐reduction on the transfusion reactions to red blood cells concentrates [Effet de la déleucocytation des concentrés érythrocytaires sur les réactions transfusionnelles]. Transfusion Clinique et Biologique 2010;17(1):14‐9. [PUBMED: 20106700] - PubMed
Nebeker 2004
    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795‐801. [PUBMED: 15148066] - PubMed
Phelan 2007
    1. Phelan HA, Sperry JL, Friese RS. Leukoreduction before red blood cell transfusion has no impact on mortality in trauma patients. Journal of Surgical Research 2007;138(1):32‐6. [PUBMED: 17161430] - PubMed
Renaudier 2009
    1. Renaudier P, Rebibo D, Waller C, Schlanger S, Vo Mai MP, Ounnoughene N, et al. Pulmonary complications of transfusion (TACO‐TRALI) [Complications pulmonaires de la transfusion (TACO–TRALI)]. Transfusion Clinique et Biologique 2009;16(2):218‐32. [PUBMED: 19446484] - PubMed
RevMan 2014 [Computer program]
    1. The Cochrane Collaboration, The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, The Nordic Cochrane Centre, 2014.
Rohde 2014
    1. Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L, et al. Health care‐associated infection after red blood cell transfusion: a systematic review and meta‐analysis. JAMA 2014;311(13):1317‐26. [PUBMED: 24691607] - PMC - PubMed
Rühl 2009
    1. Rühl H, Bein G, Sachs UJ. Transfusion‐associated graft‐versus‐host disease. Transfusion Medicine Reviews 2009;23(1):62‐71. [PUBMED: 19056035] - PubMed
Sachs 2010
    1. Sachs UJ. Non‐infectious serious hazards in plasma transfusion. Transfusion and Apheresis Science 2010;43(3):381‐6. [PUBMED: 20934385] - PubMed
Sachs 2011
    1. Sachs UJ, Wasel W, Bayat B, Bohle RM, Hattar K, Berghöfer H, et al. Mechanism of transfusion‐related acute lung injury induced by HLA class II antibodies. Blood 2011;117(2):669‐77. [PUBMED: 21030555] - PubMed
Schulz 2010
    1. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine 2010;8:18. [PUBMED: 20334633] - PMC - PubMed
Shapiro 2004
    1. Shapiro MJ. To filter blood or universal leukoreduction: what is the answer?. Critical Care 2004;8 Suppl 2:S27‐30. [PUBMED: 15196319] - PMC - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Tenorio 2007
    1. Tenorio GC, Gupte SC, Munker R. Transfusion Medicine and Immunohematology. In: Munker R, Hiller E, Glass J, Paquette R editor(s). Modern Hematology. 2nd Edition. Totowa, NJ: Humana Press Inc, 2007:401‐32. [ISBN‐13: 978‐1‐58829‐557‐6]
Theusinger 2009
    1. Theusinger OM, Spahn DR, Ganter MT. Transfusion in trauma: why and how should we change our current practice?. Current Opinion in Anaesthesiology 2009;22(2):305‐12. [PUBMED: 19390257] - PubMed
Thorlund 2011 [Computer program]
    1. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Version available from www.ctu.dk/tsa. Copenhagen, Denmark: Copenhagen Trial Unit: Centre for Clinical Intervention Research, 2011.
Tien 2007
    1. Tien H, Nascimento B Jr, Callum J, Rizoli S. An approach to transfusion and hemorrhage in trauma: current perspectives on restrictive transfusion strategies. Canadian Journal of Surgery 2007;50(3):202‐9. [PUBMED: 17568492] - PMC - PubMed
Tobian 2011
    1. Tobian AA, Savage WJ, Tisch DJ, Thoman S, King KE, Ness PM. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011;51(8):1676‐83. [PUBMED: 21214585] - PubMed
Toy 2005
    1. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al. Transfusion‐related acute lung injury: definition and review. Critical Care Medicine 2005;33(4):721‐6. [PUBMED: 15818095] - PubMed
Triulzi 2009
    1. Triulzi DJ. Transfusion‐related acute lung injury: current concepts for the clinician. Anesthesia and Analgesia 2009;108(3):770‐6. [PUBMED: 19224781] - PubMed
Tsai 2010
    1. Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. oxygen delivery in transfusion with "fresh" and "old" red blood cells: the experimental evidence. Transfusion and Apheresis Science 2010;43(1):69‐78. [PUBMED: 20646963] - PMC - PubMed
Tsantes 2014
    1. Tsantes AE, Kyriakou E, Nikolopoulos GK, Stylos D, Sidhom M, Bonovas S, et al. Cost‐effectiveness of leucoreduction for prevention of febrile non‐haemolytic transfusion reactions. Blood Transfusion 2014;12(2):232‐7. [PUBMED: 24931843] - PMC - PubMed
Vamvakas 1996
    1. Vamvakas EC, Carven JH, Hibberd PL. Blood transfusion and infection after colorectal cancer surgery. Transfusion 1996;36(11‐12):1000‐8. [PUBMED: 8937412] - PubMed
Vamvakas 2001
    1. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion‐associated immunomodulation: fact or fiction?. Blood 2001;97(5):1180‐95. [PUBMED: 11222359] - PubMed
Vamvakas 2006
    1. Vamvakas EC. Deleterious clinical effects of allogenic blood tranfusion‐related immunomodulation. Facts or fiction? An update through 2005. American Journal of Clinical Pathology 2006;126(Suppl 1):S71‐85. [DOI: 10.1309/9B7RWAYVVLCL58WW] - DOI
Vamvakas 2009
    1. Vamvakas EC, Blajchman MA. Transfusion‐related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113(15):3406‐17. [PUBMED: 19188662 ] - PubMed
Wagner 2004
    1. Wagner SJ. Transfusion‐transmitted bacterial infection: risks, sources and interventions. Vox Sanguinis 2004;86(3):157‐63. [PUBMED: 15078249] - PubMed
Watkins 2008
    1. Watkins TR, Rubenfeld GD, Martin TR, Nester TA, Caldwell E, Billgren J, et al. Effects of leukoreduced blood on acute lung injury after trauma: a randomized controlled trial. Critical Care Medicine 2008;36(5):1493‐9. [PUBMED: 18434890] - PubMed
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. [PUBMED: 18083463] - PubMed

References to other published versions of this review

Simancas‐Racines 2012
    1. Simancas‐Racines D, Martí‐Carvajal AJ, Hidalgo R, Bangdiwala S. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD009745] - DOI - PMC - PubMed

Publication types